Becker's Healthcare December 16, 2024
Jakob Emerson

The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a November report from HHS.

In 2024, the U.S. list prices for a one-month supply for most GLP-1s are stable or increasing, but after payer negotiations and rebates, net prices for many GLP-1s have decreased since 2022. Net prices for GLP-1s are between 24% and 73% lower than list prices, indicating that most insurers are paying less than the manufacturer’s list price.

“The future path of prices of drugs in this class will be affected by the number of...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Govt Agencies, HHS, Insurance, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Bringing Systems Thinking To Drug Value Assessment
As medication prices rise, hospitals turn to drugmakers
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal
Beam base editing therapy gets ‘proof of concept’ in rare lung disease

Share This Article